Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
None
None
Single group
GLP-1 Receptor Agonists
DrugGLP-1 RAs in lymphedema
Patient reported quality of life outcome using LLIS
Lymphedema Life Impact Scale
Physiological improvement
Limb volume Bioimpedance BMI Incidence of cellulitis Compression use
Click on the lead sponsor to view all of their trials.
